Oct 5 2012
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced that it was awarded a Small Business
Innovation Research (SBIR) grant by the National Cancer Institute (NCI)
of the National Institutes of Health (NIH). The grant provides funding
for a project enabling the discovery and preclinical development of
sd-rxRNAs® as potential therapy for retinoblastoma, a pediatric ocular
malignancy. The project will be completed in collaboration with Dr.
David Cobrinik and colleagues at the Memorial Sloan-Kettering Cancer
Center.
Dr. Cobrinik commented, "Prior studies performed by RXi and their
collaborators at the University of Massachusetts, demonstrated that
self-delivering sd-rxRNAs can penetrate the retina and
regulate retinal gene expression. As retinoblastomas form within the
retina, we hypothesized that sd-rxRNAs might also regulate gene
expression in intraocular retinoblastoma cells. This SBIR award will
enable us to test this hypothesis, possibly extending the application of
sd-rxRNAs from ophthalmic diseases to the cancer setting."
RXi has been awarded approximately $300,000 to fund the collaborative
project over six months. Under this grant (R43CA165899), entitled
"Development of sd-rxRNAs® as Therapy for Retinoblastoma and Other
Malignancies", sd-rxRNA compounds will be developed to silence one or
more targets critical to retinoblastoma cell growth and survival. The
sd-rxRNA compounds will be evaluated for efficacy in in vivo
models of retinoblastoma by the Cobrinik lab.
"We are honored to have the opportunity to collaborate with the team at
Memorial Sloan-Kettering, and are very pleased to have received
financial support from the NCI to further the development of our novel
RNAi compounds as potential therapeutics for ocular cancer," said Pamela
Pavco, Chief Development Officer at RXi Pharmaceuticals. "The grant
process is highly competitive, and this award serves to recognize and
support the therapeutic potential of RXI's proprietary RNAi platform."